• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ligand Pharm (NQ: LGND )

    110.04 +4.34 (+4.11%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Ligand Pharm

    < Previous 1 2 3 Next >
    Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
    Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment... 
    From Palvella Therapeutics
    Via GlobeNewswire
    Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Reports Second Quarter 2024 Financial Results
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    5 Best Short-Term Stocks to Consider Investing In
    Looking for the best short-term stocks? Explore our top picks and learn how to navigate the risks and opportunities in fast-paced stock trading. 
    Via MarketBeat
    Ligand to Acquire APEIRON Biologics AG for $100 Million
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Lifecore Biomedical Announces Cooperation Agreement with 22NW
    Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board 
    From Lifecore Biomedical, Inc.
    Via GlobeNewswire
    Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand to Participate in Upcoming Investor Conferences
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Reports First Quarter 2024 Financial Results
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pharmaceuticals Inc. (NASDAQ: LGND) Making Surprising Moves in Tuesday Session
    Via Investor Brand Network
    Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
    From Palvella Therapeutics
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.